UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 2, 2020
PARALLAX HEALTH SCIENCES, INC.
(Exact name of Company as specified in its charter)
Nevada | 000-52534 | 46-4733512 |
(State or other jurisdiction | (Commission File Number) | (IRS Employer |
of Incorporation) |
| Identification Number) |
| 1327 Ocean Avenue, Suite B Santa Monica, CA 90401 (Address of principal executive offices)
310-899-4442 (Registrant’s Telephone Number) |
|
Copy of all Communications to: Peter V. Hogan Buchalter 1000 Wilshire Boulevard, Suite 1500 Los Angeles, CA 90017 (213) 891-0700
| ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions: | |
|
|
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
As used in this current report and unless otherwise indicated, the terms "we", "us", "our", “Company”, and “Parallax” mean Parallax Health Sciences, Inc., a Nevada corporation, and its subsidiaries, unless otherwise indicated.
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
The disclosures set forth in Item 5.02 are incorporated by into this Item 1.01 by reference.
ITEM 5.02DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On February 2, 2020, Mr. David Appell resigned as Chief Operating Officer of Parallax Health Sciences, Inc. (the "Company"). Mr. Appell’s resignation was not the result of a disagreement with the Company on any matters relating to the Company's operations, policies or practices.
In conjunction with his resignation, the Company and Mr. Appell agreed for Mr. Appell to serve as Managing Director (the “Agreement”) of the Company’s wholly-owned subsidiary Parallax Communications, Inc. (“PCOM”).
Pursuant to the Agreement, Mr. Appell will provide business advisory and strategic planning advice to the Company with PCOM. In exchange for these services, Mr. Appell will be paid $2,000 per month plus medical benefits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| PARALLAX HEALTH SCIENCES, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dated: February 7, 2019 | /s/ Calli R. Bucci |
|
|
| Calli R. Bucci |
|
|
| Chief Financial Officer |
|
|
|
|
|